Below is an overview of all our licensing and sublicensing agreements. For more information, click on the product, patent holder, generic partner or product developer you are interested in.
//= $num; ?> Patent Holders//= _x('Pharmaceutical Companies', 'theme', 'mpp'); ?>
|LOPINAVIR, RITONAVIR (LPV/r)||78.9%|
|LOPINAVIR, RITONAVIR (LPV/r) PAEDIATRICS||98.8%|
|TENOFOVIR ALAFENAMIDE (TAF)||89.8%|
|TENOFOVIR DISOPROXIL FUMARATE (TDF)||89.8%|
|RALTEGRAVIR (RAL) PAEDIATRICS||98%|
|ABACAVIR – PAEDIATRICS (ABC)||99.3%|
|DOLUTEGRAVIR - ADULT (DTG)||90%|
|DOLUTEGRAVIR - PAEDIATRICS (DTG)||99%|
//= $num; ?> Research Institutions
*Effective coverage = percentage of people living with the disease in all developing countries that can benefit from the licence.
In addition to these agreements, the MPP signed a licence with the University of Liverpool for the university’s Solid Drug Nanoparticle technology; it has also concluded a licence agreement for patents related to darunavir (DRV) with the US National Institutes of Health (but additional licences are needed to allow for generic manufacture); and it worked with Janssen Pharmaceuticals and Boehringer Ingelheim to extend their non-assert policies for paediatric darunavir formulations and nevirapine, ensuring that the two companies will not assert their patent rights in many more developing countries. The MPP also signed a licensing agreement with Pharco Pharmaceuticals on ravidasvir.